Skip to main content

Table 2 Constant HR estimatesa from a fixed-effects NMA of RFS/DFS in patients with resected stage II–IV melanoma

From: Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

  1. aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatment indicated in that row versus the treatment indicated in that column; bolded values are statistically significant at the 0.05 significance level
  2. DFS disease-free survival, HR hazard ratio, IFN interferon, NMA network meta-analysis, RFS recurrence-free survival